NurExone demonstrates extended therapeutic window of ExoPTEN after spinal cord injury in preclinical study Page 1

TORONTO and HAIFA, Israel, September 6, 2024 (GLOBE NEWSWIRE) – NurExone Biologic Inc. (TSXV: NRX), (OTCQB: NRXBF), (Germany: J90) (the “Pursue” or “OnlyExone”) is pleased to announce compelling new findings highlighting the therapeutic potential of ExoPTEN for patients with spinal cord injury. In a recent preclinical study using a spinal cord compression model, our team demonstrated that ExoPTEN has a strong ability to target and accumulate at the injury site, even when administered up to one week after injury. This finding is critical as it suggests a long window of time during which the treatment can be effectively delivered.

Dr. Lior Shaltiel, CEO of NurExone, emphasized the importance of this capability for practice, stating, “The ability to treat patients up to 7 days after injury could broaden the pool of patients eligible for treatment and extend the window of efficacy, leading to improved recovery. In addition, the findings may significantly improve the ability to recruit more patients to clinical trials and increase the number of treatable patients without being limited by a short therapeutic window and hospital management challenges.” He continued, “As the global incidence of spinal cord injury is estimated at 250,000 to 500,000,^I cases annually, and given that some patients do not receive immediate treatment, the potential market for a therapy effective up to one week after injury could be substantial.”

As shown in Figure 1, ExoPTEN was fluorescently labeled and administered to rats with induced spinal cord compression injuries. Administration occurred at four different time points: on the day of injury (day 0), 3 days later, 5 days later, and 7 days later. Administration was performed together and with an untreated control group. The goal was to assess how well ExoPTEN targets and accumulates at an injury site over time.

Using a modern in vivo imaging system (“IVIS”), ExoPTEN was observed to accumulate continuously at the injury site. A remarkable gradient in homing capacity was observed, with later administration times leading to increasingly higher levels of accumulation. The highest accumulation was observed in those treated 7 days post-injury, with a statistically significant dose-dependent accumulation of ExoPTEN at the injury site.

Discuss the values ​​contained